Waldencast plc (WALDW)
| Market Cap | 121.79M -60.8% |
| Revenue (ttm) | 272.07M -0.7% |
| Net Income | -229.75M |
| EPS | -2.01 |
| Shares Out | 118.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 142,194 |
| Open | 0.0048 |
| Previous Close | 0.0056 |
| Day's Range | 0.0034 - 0.0053 |
| 52-Week Range | 0.0026 - 0.0720 |
| Beta | -0.07 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 13, 2026 |
About WALDW
Waldencast plc operates in the beauty and wellness industry in the United States, Canada, Europe, the Middle East, India, Australia, and New Zealand. The company operates through two segments, Obagi Medical and Milk Makeup. It offers skin care products to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and protect and enhance skin tone and texture; cosmetics; and other beauty products. In addition, the company provides foundation, concealer, primer, blush, setting spray, and bronzer categories, as w... [Read more]
News
Waldencast to voluntarily delist from Nasdaq and deregister its securities
Waldencast (WALD) has filed a Form 25 with the SEC to remove its Class A ordinary shares, par value $0.0001 per share, and its redeemable warrants, each whole warrant exercisable…
Waldencast plc Files Form 25 to Voluntary Delist from Nasdaq and Deregister its Securities under the Exchange Act
LONDON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”) today announced that it has filed a Form 25 (Notification of Removal from Listing) with the Sec...
Waldencast to voluntarily delist from Nasdaq
Waldencast (WALD) announced that it has notified the Nasdaq Stock Market of its decision to voluntarily delist its Class A ordinary shares and its redeemable warrants, each whole warrant exercisable…
Waldencast plc Announces Intention to Voluntarily Delist from Nasdaq and Deregister its Securities under the Exchange Act
Board to recommend that shareholders approve renaming the Company Milk Makeup plc The Company's Board of Directors has approved the voluntary delisting of the Company's Class A Ordinary Shares and War...
Waldencast director buys $505.6K in common stock
In a regulatory filing, Waldencast (WALD) disclosed that its director Cristiano Souza bought 335K shares of common stock on August 28th for a total transaction of $505.6K. Shares are up…
Waldencast Announces Completion of the Sale of Obagi Medical to Bridgepoint
LONDON, July 30, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or “the Company”) today announced that it completed the previously announced sale of its Obagi Medical dermatologi...
Waldencast announces regulatory approval of Obagi dermal filler
Waldencast (WALD) announced that the U.S. Food and Drug Administration has approved Obagi saypha ChIQ injectable hyaluronic acid gel, the latest addition to the Obagi injectable portfolio under the Ob...
Obagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel
LONDON, June 15, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that the U.S. Food and Drug ...
Waldencast price target raised to $3 from $2 at Canaccord
Canaccord raised the firm’s price target on Waldencast (WALD) to $3 from $2 and keeps a Buy rating on the shares. The firm noted the company announced they have entered…
Waldencast to sell Obagi Medical to Bridgepoint for up to $460M
Waldencast (WALD) announced that it has entered into a definitive agreement to sell its Obagi Medical dermatological skincare and aesthetics business to Bridgepoint in a transaction valued at up to…
Waldencast Announces Sale of Obagi Medical to Bridgepoint
LONDON, June 01, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or “the Company”) today announced that it has entered into a definitive agreement to sell its Obagi Medical dermat...
Obagi Medical Shares New Data on Recent Innovations at Music City Symposium for Cosmetic Advances & Laser Education (SCALE) Meeting
Data from the ALOHA Program and NU-GEN™ Cellular Renewal Serum Showcase Results to Help Drive Practice Success Data from the ALOHA Program and NU-GEN™ Cellular Renewal Serum Showcase Results to Help D...
Obagi and Next Health Partner to Launch “The Skin Recharge Station” Pop-Up Experience
A multi-city pop-up introducing consumers to the future of skincare and longevity innovation A multi-city pop-up introducing consumers to the future of skincare and longevity innovation
Obagi Medical Unveils New Mineral Sunscreen Designed to Protect Sensitive and Post-Procedure Skin*
Sun Shield™ Mineral UV Barrier Protect Broad Spectrum SPF 40 delivers advanced mineral protection with skincare benefits for daily defense Sun Shield™ Mineral UV Barrier Protect Broad Spectrum SPF 40 ...
Waldencast announces conclusion of SEC investigation
LONDON, April 28, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, announced today that it was notified by the...
Obagi Medical Introduces NU-GEN™ Cellular Renewal Serum Designed to Visibly Rewind Skin's Age and Restore Visible Youthfulness
The clinically proven formula pairs NAD+ with its precursors to replenish skin cells and address nine signs of skin aging for healthier, more resilient-looking skin The clinically proven formula pairs...
Obagi Medical and ProMD Announce Collaboration in the ALOHA Program to Advance Clinical Evidence with Obagi® saypha® MagIQ™
ProMD's multi-location physician led network will participate in Obagi's ALOHA Program as part of a structured evaluation of MagIQ and integrated skincare protocols to providers across multiple states...
Waldencast price target lowered to $2.50 from $3.50 at Alliance Global
Alliance Global analyst Aaron Grey lowered the firm’s price target on Waldencast (WALD) to $2.50 from $3.50 and keeps a Buy rating on the shares following the Q4 report. The…
Waldencast price target lowered to $2 from $3 at Telsey Advisory
Telsey Advisory lowered the firm’s price target on Waldencast (WALD) to $2 from $3 and keeps a Market Perform rating on the shares. The company’s Q4 results fell short of…
Waldencast price target lowered to $2 from $4 at Canaccord
Canaccord lowered the firm’s price target on Waldencast (WALD) to $2 from $4 and keeps a Buy rating on the shares. The firm said they reported their 3Q, 4Q, and…
Waldencast price target lowered to $2 from $4 at Canaccord
Canaccord lowered the firm’s price target on Waldencast (WALD) to $2 from $4 and keeps a Buy rating on the shares.
Waldencast reports Q4 revenue $72M vs. $72.1M last year
Reports Q4 adjusted EBITDA $6.6M vs. $11.2M last year. “Fiscal 2025 was a defining year of transformation for Waldencast (WALD), as we focused on strengthening our operating platform and sharpening…
Waldencast Reports Q4 2025 and FY 2025 Financial Results
FY 2025 net revenue of $272.1 million, flat to FY 2024, and Adjusted EBITDA of $16.1 million Q4 2025 net revenue of $72.0 million, flat to Q4 2024 and Adjusted EBITDA of $6.6 million Obagi Medical see...
Waldencast Earnings release: Q4 2025
Waldencast released its Q4 2025 earnings on March 13, 2026, summarizing the period's financial results.
Waldencast Annual report: Q4 2025
Waldencast has published its Q4 2025 annual report on March 13, 2026.